Sanofi Drug Shows Long-Term Benefit
Blueprint Medicines, a Sanofi company, announced four-year data from its PIONEER study on the drug AYVAKIT. The results show a sustained benefit and long-term safety for patients with indolent systemic mastocytosis, a rare blood disorder. The data was presented at the 2026 American Academy of Allergy, Asthma & Immunology annual meeting.
AYVAKIT, known chemically as avapritinib, is a targeted therapy designed to inhibit KIT D816V, the genetic mutation that is the primary driver in approximately 95% of systemic mastocytosis cases. This mechanism marks a shift from supportive care to a disease-modifying treatment for this condition. French pharmaceutical giant Sanofi acquired Blueprint Medicines in mid-2025 for about $9.1 billion, in one of its largest deals in recent years. The acquisition gave Sanofi control of AYVAKIT and strengthened its portfolio in rare immunological diseases. Indolent systemic mastocytosis (ISM) accounts for the vast majority of systemic mastocytosis cases and has an estimated prevalence of around 1 in every 10,000 people. Patients often experience a wide range of debilitating symptoms, including fatigue, brain fog, skin lesions, and gastrointestinal issues. Before its approval for ISM in May 2023, avapritinib was first approved by the FDA in January 2020 for a specific type of gastrointestinal stromal tumor (GIST). Its indication was later expanded to advanced systemic mastocytosis in June 2021. The pivotal Part 2 of the PIONEER trial involved 212 adult patients with moderate-to-severe ISM. In this portion of the study, 141 patients received a 25 mg daily dose of AYVAKIT alongside best supportive care, while 71 patients received a placebo with supportive care for a 24-week period. At the time of the acquisition, AYVAKIT had generated sales of $479 million in the previous year. Projections from Blueprint Medicines estimated the drug has a peak sales potential of $2 billion.
